Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L.
Di Bella N, et al. Among authors: wang y.
Blood. 2010 Jan 21;115(3):475-80. doi: 10.1182/blood-2009-08-233155. Epub 2009 Nov 19.
Blood. 2010.
PMID: 19965689
Free article.
Clinical Trial.